Sandoz Reports Results of Omnitrope (biosimilar- somatropin) in PATRO Children Study for the Treatment of Turner Syndrome
Shots:
- The PATRO Children- post marketing surveillance study evaluates biosimilar rhGH (Omnitrope) vs reference rhGH (Genotropin) in 348 children with TS at 130 centers across EU. In this study- 81.6% were rhGH naïve- and 90.2% were prepubertal
- The results demonstrated that the therapy was safe & effective in real-life clinical practice- was generally well tolerated with no unexpected safety signals.
- Mean duration of treatment was 38.5mos.- 48.9% experienced AEs substantial height gains in prepubertal individuals aged 3+ yrs. Additionally- 49.4% of patients discontinued the study
| Ref: Centre for Biosimilar| Image: Reuters
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com